{
    "hands_on_practices": [
        {
            "introduction": "The interaction between a peptide and an MHC molecule is a specific biochemical event, and its strength can be quantified. This exercise bridges molecular immunology with thermodynamics by asking you to calculate the Gibbs free energy of binding, $\\Delta G^{\\circ}$, from experimentally measured dissociation constants, $K_d$. By converting affinity data into energy values, you can directly compare how stably different HLA alleles present the same peptide epitope, a key factor in determining immunogenicity. ",
            "id": "4605187",
            "problem": "A cytotoxic T lymphocyte recognizes antigenic peptides bound by Major Histocompatibility Complex (MHC) class I molecules encoded by Human Leukocyte Antigen (HLA) alleles. For a single nonamer peptide epitope, equilibrium dissociation constants $K_d$ (defined relative to the $1\\ \\mathrm{M}$ standard state so that $\\ln K_d$ is dimensionless) were experimentally measured for three HLA-A alleles: HLA-A*02:01 with $K_d = 3.0 \\times 10^{-8}\\ \\mathrm{M}$, HLA-A*24:02 with $K_d = 2.0 \\times 10^{-6}\\ \\mathrm{M}$, and HLA-A*03:01 with $K_d = 4.0 \\times 10^{-7}\\ \\mathrm{M}$. Using the equilibrium thermodynamic relation $\\Delta G^{\\circ} = RT \\ln K_d$ and the absolute temperature $T = 310\\ \\mathrm{K}$, where $R = 8.314\\ \\mathrm{J\\,mol^{-1}\\,K^{-1}}$, compute $\\Delta G^{\\circ}$ for each allele, identify which allele most stably presents the epitope (i.e., has the lowest $\\Delta G^{\\circ}$), and for your final reported value provide the minimum $\\Delta G^{\\circ}$ among the three in $\\mathrm{kJ\\,mol^{-1}}$. Round your final reported value to four significant figures and express the energy in $\\mathrm{kJ\\,mol^{-1}}$.",
            "solution": "The problem asks for the calculation of the standard Gibbs free energy of binding, $\\Delta G^{\\circ}$, for peptide binding to three different Major Histocompatibility Complex (MHC) class I alleles, and to identify the minimum $\\Delta G^{\\circ}$ among them.\n\nThe fundamental relationship between the standard Gibbs free energy of binding and the equilibrium dissociation constant, $K_d$, is given by the equation:\n$$\n\\Delta G^{\\circ} = RT \\ln K_d\n$$\nwhere $R$ is the ideal gas constant, $T$ is the absolute temperature, and $K_d$ is the equilibrium dissociation constant. The problem specifies that $K_d$ is defined relative to the $1\\ \\mathrm{M}$ standard state, which renders the argument of the logarithm, $\\ln K_d$, dimensionless.\n\nThe given values are:\n- Ideal gas constant, $R = 8.314\\ \\mathrm{J\\,mol^{-1}\\,K^{-1}}$.\n- Absolute temperature, $T = 310\\ \\mathrm{K}$.\n- Equilibrium dissociation constants for the three alleles:\n  - For HLA-A*02:01: $K_{d,1} = 3.0 \\times 10^{-8}$\n  - For HLA-A*24:02: $K_{d,2} = 2.0 \\times 10^{-6}$\n  - For HLA-A*03:01: $K_{d,3} = 4.0 \\times 10^{-7}$\n\nThe stability of the peptide-MHC complex is inversely related to the dissociation constant $K_d$. A smaller $K_d$ indicates less dissociation at equilibrium and therefore a more stable complex. The corresponding standard Gibbs free energy change, $\\Delta G^{\\circ}$, will be more negative for a more stable complex. Since all the given $K_d$ values are less than $1$, the term $\\ln K_d$ will be negative, leading to a negative $\\Delta G^{\\circ}$, which signifies that the bound state is more stable than the dissociated state under standard conditions.\n\nTo find the allele that most stably presents the epitope, we must identify the one with the smallest $K_d$, which will yield the lowest (most negative) $\\Delta G^{\\circ}$. We compare the given $K_d$ values:\n$$\n3.0 \\times 10^{-8} < 4.0 \\times 10^{-7} < 2.0 \\times 10^{-6}\n$$\nThis inequality shows that $K_{d,1} < K_{d,3} < K_{d,2}$. Therefore, the HLA-A*02:01 allele forms the most stable complex with the peptide and will have the minimum $\\Delta G^{\\circ}$.\n\nThe problem requires us to compute this minimum $\\Delta G^{\\circ}$. We will use the value of $K_d$ for HLA-A*02:01, which is $K_{d,1} = 3.0 \\times 10^{-8}$.\n\nFirst, we calculate the product $RT$:\n$$\nRT = (8.314\\ \\mathrm{J\\,mol^{-1}\\,K^{-1}}) \\times (310\\ \\mathrm{K}) = 2577.34\\ \\mathrm{J\\,mol^{-1}}\n$$\nNext, we calculate $\\Delta G^{\\circ}$ for this allele:\n$$\n\\Delta G^{\\circ}_{\\min} = RT \\ln(K_{d,1}) = (2577.34\\ \\mathrm{J\\,mol^{-1}}) \\times \\ln(3.0 \\times 10^{-8})\n$$\nCalculating the natural logarithm:\n$$\n\\ln(3.0 \\times 10^{-8}) \\approx -17.322105\n$$\nNow, we compute $\\Delta G^{\\circ}_{\\min}$:\n$$\n\\Delta G^{\\circ}_{\\min} \\approx (2577.34\\ \\mathrm{J\\,mol^{-1}}) \\times (-17.322105) \\approx -44637.5\\ \\mathrm{J\\,mol^{-1}}\n$$\nThe problem asks for the answer in units of $\\mathrm{kJ\\,mol^{-1}}$. To convert from $\\mathrm{J\\,mol^{-1}}$ to $\\mathrm{kJ\\,mol^{-1}}$, we divide by $1000$:\n$$\n\\Delta G^{\\circ}_{\\min} \\approx -44.6375\\ \\mathrm{kJ\\,mol^{-1}}\n$$\nFinally, we must round the result to four significant figures. The first four significant figures are $4$, $4$, $6$, $3$. The fifth significant digit is $7$, which is greater than or equal to $5$, so we round up the last digit.\n$$\n\\Delta G^{\\circ}_{\\min} \\approx -44.64\\ \\mathrm{kJ\\,mol^{-1}}\n$$\nFor completeness, we can also calculate the $\\Delta G^{\\circ}$ values for the other two alleles to confirm our reasoning.\nFor HLA-A*24:02 ($K_{d,2} = 2.0 \\times 10^{-6}$):\n$$\n\\Delta G^{\\circ}_2 = (2577.34\\ \\mathrm{J\\,mol^{-1}}) \\times \\ln(2.0 \\times 10^{-6}) \\approx (2577.34) \\times (-13.1223) \\approx -33818.5\\ \\mathrm{J\\,mol^{-1}} = -33.82\\ \\mathrm{kJ\\,mol^{-1}}\n$$\nFor HLA-A*03:01 ($K_{d,3} = 4.0 \\times 10^{-7}$):\n$$\n\\Delta G^{\\circ}_3 = (2577.34\\ \\mathrm{J\\,mol^{-1}}) \\times \\ln(4.0 \\times 10^{-7}) \\approx (2577.34) \\times (-14.7318) \\approx -37968.9\\ \\mathrm{J\\,mol^{-1}} = -37.97\\ \\mathrm{kJ\\,mol^{-1}}\n$$\nComparing the three values: $-44.64\\ \\mathrm{kJ\\,mol^{-1}}$, $-33.82\\ \\mathrm{kJ\\,mol^{-1}}$, and $-37.97\\ \\mathrm{kJ\\,mol^{-1}}$. The minimum value is indeed $-44.64\\ \\mathrm{kJ\\,mol^{-1}}$, corresponding to the HLA-A*02:01 allele.",
            "answer": "$$\\boxed{-44.64}$$"
        },
        {
            "introduction": "While direct measurement of binding affinity provides definitive data, it is often necessary to predict which peptides from a pathogen's proteome will bind to a given MHC molecule. This practice introduces you to the logic of immunoinformatics, using a simplified scoring model based on anchor residue preferences to estimate binding likelihood. By applying a position-specific scoring matrix and a logistic function, you will learn the core principles behind the algorithms that are essential for modern vaccine design and epitope discovery. ",
            "id": "4605170",
            "problem": "A cytotoxic T lymphocyte recognizes peptides bound to Major Histocompatibility Complex (MHC) class I molecules on infected cells. Human Leukocyte Antigen (HLA) class I alleles, such as Human Leukocyte Antigen-B*07:02 (HLA-B*07:02), bind peptides typically of length $8$–$10$ with critical “anchor” residues that fit into conserved pockets of the binding groove. For HLA-B*07:02, literature and experimental consensus support anchors at peptide position $2$ (the B-pocket) and the C-terminal position (position $\\Omega$; for a $9$-mer, position $9$) in the F-pocket. A motif-based position-specific scoring approach can approximate binding likelihood by summing residue-specific contributions at anchor and auxiliary positions, followed by a logistic transform to map the score to a probability.\n\nConsider the $9$-mer peptide sequence “APRGVYELI” and the following scientifically plausible motif preferences for HLA-B*07:02:\n\n- Anchor position $2$ (B-pocket) contributions $w_{2}(\\cdot)$:\n  - $w_{2}(\\text{P}) = 2.0$, $w_{2}(\\text{A}) = 0.5$, $w_{2}(\\text{S}) = 0.3$, all other residues contribute $0$.\n- Anchor position $9$ (F-pocket; position $\\Omega$ for a $9$-mer) contributions $w_{9}(\\cdot)$:\n  - $w_{9}(\\text{L}) = 1.8$, $w_{9}(\\text{I}) = 1.5$, $w_{9}(\\text{F}) = 1.6$, $w_{9}(\\text{V}) = 1.2$, $w_{9}(\\text{M}) = 1.4$, all other residues contribute $0$.\n- Auxiliary position $3$ contributions $w_{3}(\\cdot)$:\n  - $w_{3}(\\text{R}) = 0.4$, $w_{3}(\\text{K}) = 0.3$, all other residues contribute $0$.\n- Auxiliary position $5$ hydrophobic preference $w_{5}(\\cdot)$:\n  - For $\\{\\text{A}, \\text{V}, \\text{L}, \\text{I}, \\text{F}, \\text{M}, \\text{Y}\\}$, $w_{5}(\\cdot) = 0.2$, otherwise $0$.\n\nDefine the motif match score $S$ as the sum of these position-specific weights over the peptide:\n$$\nS \\equiv w_{2}(X_{2}) + w_{9}(X_{9}) + w_{3}(X_{3}) + w_{5}(X_{5}),\n$$\nwhere $X_{i}$ denotes the residue at position $i$ of the peptide.\n\nMap $S$ to an estimated binding probability $p$ using a logistic function calibrated for a motif-based classifier:\n$$\np = \\frac{1}{1 + \\exp\\!\\big(-(\\alpha S + \\beta)\\big)},\n$$\nwith calibration constants $\\alpha = 0.70$ and $\\beta = -1.00$.\n\nTasks:\n- Using fundamental definitions of MHC class I anchor positions and the provided motif preferences, identify the most likely anchor residues in the peptide “APRGVYELI”.\n- Compute the motif match score $S$ for this peptide.\n- Compute the binding probability $p$ using the logistic mapping above.\n\nRound your final numerical answer for $p$ to four significant figures. Express your final answer as a pure number without any units.",
            "solution": "The recognition of peptides by Major Histocompatibility Complex (MHC) class I relies on anchor residues occupying conserved pockets, particularly the B-pocket at position $2$ and the F-pocket at position $\\Omega$ (position $9$ for a $9$-mer peptide). For Human Leukocyte Antigen-B*07:02 (HLA-B*07:02), well-established preferences include a strong preference for proline at position $2$, and hydrophobic/aromatic residues such as leucine, isoleucine, valine, phenylalanine, and methionine at the C-terminal position.\n\nStep $1$: Identify anchor residues from the peptide sequence.\n\nThe peptide is “APRGVYELI”, which we index as:\n- $X_{1} = \\text{A}$,\n- $X_{2} = \\text{P}$,\n- $X_{3} = \\text{R}$,\n- $X_{4} = \\text{G}$,\n- $X_{5} = \\text{V}$,\n- $X_{6} = \\text{Y}$,\n- $X_{7} = \\text{E}$,\n- $X_{8} = \\text{L}$,\n- $X_{9} = \\text{I}$.\n\nBy motif definition, the anchor positions for HLA-B*07:02 in a $9$-mer are positions $2$ and $9$. Thus, the most likely anchor residues in this peptide are $X_{2} = \\text{P}$ and $X_{9} = \\text{I}$.\n\nStep $2$: Compute the motif match score $S$ using the provided weights.\n\nWe use\n$$\nS = w_{2}(X_{2}) + w_{9}(X_{9}) + w_{3}(X_{3}) + w_{5}(X_{5}).\n$$\n\nEvaluate each term:\n- At position $2$: $X_{2} = \\text{P}$, so $w_{2}(\\text{P}) = 2.0$.\n- At position $9$: $X_{9} = \\text{I}$, so $w_{9}(\\text{I}) = 1.5$.\n- At position $3$: $X_{3} = \\text{R}$, so $w_{3}(\\text{R}) = 0.4$.\n- At position $5$: $X_{5} = \\text{V}$, which is hydrophobic and in the specified set, so $w_{5}(\\text{V}) = 0.2$.\n\nSum the contributions:\n$$\nS = 2.0 + 1.5 + 0.4 + 0.2 = 4.1.\n$$\n\nStep $3$: Map $S$ to the binding probability $p$ using the logistic function with $\\alpha = 0.70$ and $\\beta = -1.00$.\n\nCompute the linear predictor:\n$$\n\\alpha S + \\beta = 0.70 \\times 4.1 + (-1.00) = 2.87 - 1.00 = 1.87.\n$$\n\nThen compute\n$$\np = \\frac{1}{1 + \\exp\\!\\big(-(1.87)\\big)} = \\frac{1}{1 + \\exp(-1.87)}.\n$$\n\nEvaluate $\\exp(-1.87)$. Using $\\exp(1.87) \\approx 6.488296394$, we have\n$$\n\\exp(-1.87) \\approx \\frac{1}{6.488296394} \\approx 0.154124.\n$$\nTherefore,\n$$\np \\approx \\frac{1}{1 + 0.154124} = \\frac{1}{1.154124} \\approx 0.86645.\n$$\n\nRounding to four significant figures gives\n$$\np \\approx 0.8665.\n$$\n\nThus, the final rounded binding probability is $0.8665$.",
            "answer": "$$\\boxed{0.8665}$$"
        },
        {
            "introduction": "Understanding *how* an antigen is processed is as important as knowing *if* it binds to an MHC molecule. This practice challenges you to think like an experimental immunologist by designing an experiment to dissect the distinct antigen processing pathways for MHC class I and class II. By predicting the effects of specific inhibitors on different forms of an antigen, you will solidify your understanding of how cytosolic and endosomal routes lead to CD$8^{+}$ and CD$4^{+}$ T cell activation, respectively, and appreciate the critical role of experimental controls. ",
            "id": "4605036",
            "problem": "An immunology research team wants to quantify how inhibiting cytosolic versus endo/lysosomal proteolysis shifts peptide presentation on Major Histocompatibility Complex (MHC) class I versus MHC class II. They will use murine bone marrow–derived dendritic cells (BMDCs) from C57BL/6 mice and co-culture them with antigen-specific T cells. The goal is to design an experiment that discriminates effects on antigen processing from effects on peptide–MHC loading or general cytotoxicity and to predict the outcomes under appropriate controls. Base your reasoning only on the following fundamental, widely accepted facts:\n\n- MHC class I (MHC I) typically presents peptides derived from cytosolic proteins that are degraded by the proteasome and transported by Transporter associated with Antigen Processing (TAP) into the endoplasmic reticulum, where peptide loading onto MHC I occurs.\n- MHC class II (MHC II) typically presents peptides derived from endocytosed proteins that are degraded by endosomal/lysosomal proteases (for example, cathepsins) in acidified compartments, followed by loading onto MHC II after the invariant chain is degraded.\n- Providing preprocessed synthetic peptides that already fit the relevant MHC binding groove bypasses the need for upstream proteolysis.\n- Cross-presentation by dendritic cells can present exogenous antigen on MHC I via a pathway that depends on cytosolic access and proteasome activity.\n\nThe team considers the following standardized elements for their experiment design:\n\n- Antigen sources:\n  - Cytosolic ovalbumin (OVA) generated by mRNA electroporation (cOVA) to restrict antigen to the cytosol.\n  - Soluble OVA protein (sOVA) fed to BMDCs to route antigen through endocytic compartments.\n  - Synthetic OVA peptides: SIINFEKL for $H-2K^{\\mathrm{b}}$ (MHC I) and $OVA_{323–339}$ for $I-A^{\\mathrm{b}}$ (MHC II).\n- Inhibitors and timing:\n  - A proteasome inhibitor (for example, MG132) at $10\\,\\mu\\mathrm{M}$, added $1\\,\\mathrm{h}$ before antigen and maintained throughout culture.\n  - A lysosomal protease inhibitor cocktail (for example, E64d at $20\\,\\mu\\mathrm{M}$ plus pepstatin A at $10\\,\\mu\\mathrm{M}$), added $1\\,\\mathrm{h}$ before antigen and maintained throughout culture.\n  - Vehicle control (dimethyl sulfoxide, DMSO) at matched volume.\n- T cell readouts:\n  - OT-I CD$8^{+}$ T cells specific for SIINFEKL–$H-2K^{\\mathrm{b}}$ and OT-II CD$4^{+}$ T cells specific for $OVA_{323–339}$–$I-A^{\\mathrm{b}}$ are co-cultured with BMDCs at a $1{:}5$ ratio (BMDC{:}T cell).\n  - Interferon-gamma (IFN-$\\gamma$) in supernatants is measured by Enzyme-Linked Immunosorbent Assay (ELISA) at $18\\,\\mathrm{h}$ as a quantitative readout of antigen presentation–dependent T cell activation.\n- Orthogonal controls:\n  - Fluorescent OVA uptake measured by flow cytometry to confirm that inhibitors do not block antigen internalization.\n  - Viability assessed by propidium iodide exclusion to control for cytotoxicity, with viability maintained at $\\geq 90\\%$.\n\nWhich option below most appropriately specifies a valid design and the expected pattern of results, including critical controls that separate effects on processing from effects on peptide–MHC loading?\n\nA. Treat BMDCs with MG132 or E64d/pepstatin as described; deliver cOVA, sOVA, or preprocessed peptides; then co-culture with OT-I or OT-II and quantify IFN-$\\gamma$. Predicted outcomes: with cOVA, MG132 markedly reduces OT-I responses while E64d/pepstatin has no effect; with sOVA, MG132 reduces OT-I cross-presentation whereas E64d/pepstatin reduces OT-II responses; for peptide-pulsed BMDCs (SIINFEKL or $OVA_{323–339}$), neither MG132 nor E64d/pepstatin reduces IFN-$\\gamma$ from OT-I or OT-II, indicating that proteolysis is bypassed. Fluorescent OVA uptake and viability are unchanged across inhibitor and vehicle groups.\n\nB. Treat BMDCs with MG132 or E64d/pepstatin; deliver only sOVA; co-culture with OT-I and OT-II. Predicted outcomes: MG132 reduces both OT-I and OT-II responses, and E64d/pepstatin has no effect on either response. Peptide-pulsed controls are not needed because inhibitors act only upstream of peptide–MHC loading.\n\nC. Treat BMDCs with MG132 or E64d/pepstatin; deliver cOVA, sOVA, and preprocessed peptides; co-culture with OT-I and OT-II. Predicted outcomes: both inhibitors reduce OT-I and OT-II responses for all antigen formats, including preprocessed peptides, because both proteasomes and lysosomal proteases are broadly required for peptide–MHC stability. Uptake and viability controls are unnecessary.\n\nD. Treat BMDCs with MG132 or E64d/pepstatin; deliver cOVA and sOVA; co-culture only with OT-I. Predicted outcomes: MG132 reduces OT-I responses to sOVA but not to cOVA; E64d/pepstatin reduces OT-I responses to cOVA but not to sOVA. Peptide-pulsed controls are omitted because they cannot inform processing steps.\n\nSelect the single best option.",
            "solution": "### Step 1: Extract Givens\n\nThe problem statement provides the following definitions, experimental components, and conditions:\n\n- **Fundamental Principles:**\n  1.  Major Histocompatibility Complex class I ($\\mathrm{MHC\\,I}$) presents peptides from cytosolic proteins degraded by the proteasome and transported by the Transporter associated with Antigen Processing ($\\mathrm{TAP}$) into the endoplasmic reticulum.\n  2.  Major Histocompatibility Complex class II ($\\mathrm{MHC\\,II}$) presents peptides from endocytosed proteins degraded by endosomal/lysosomal proteases in acidified compartments.\n  3.  Preprocessed synthetic peptides bypass the need for upstream proteolysis.\n  4.  Cross-presentation by dendritic cells ($\\mathrm{DCs}$) loads exogenous antigen onto $\\mathrm{MHC\\,I}$ via a pathway dependent on cytosolic access and proteasome activity.\n\n- **Experimental System:**\n  - **Antigen Presenting Cells:** Murine bone marrow–derived dendritic cells ($\\mathrm{BMDCs}$) from C57BL/6 mice.\n  - **Antigen Sources:**\n    - Cytosolic ovalbumin ($\\mathrm{cOVA}$) from mRNA electroporation.\n    - Soluble ovalbumin protein ($\\mathrm{sOVA}$) added to culture.\n    - Synthetic peptide for $\\mathrm{MHC\\,I}$: $\\mathrm{SIINFEKL}$ for $H-2K^{\\mathrm{b}}$.\n    - Synthetic peptide for $\\mathrm{MHC\\,II}$: $OVA_{323–339}$ for $I-A^{\\mathrm{b}}$.\n  - **Inhibitors:**\n    - Proteasome inhibitor: $\\mathrm{MG132}$ at $10\\,\\mu\\mathrm{M}$.\n    - Lysosomal protease inhibitors: $\\mathrm{E64d}$ at $20\\,\\mu\\mathrm{M}$ plus $\\mathrm{pepstatin\\,A}$ at $10\\,\\mu\\mathrm{M}$.\n    - Vehicle Control: Dimethyl sulfoxide ($\\mathrm{DMSO}$).\n  - **T-Cell Responders:**\n    - OT-I CD$8^{+}$ T cells specific for SIINFEKL–$H-2K^{\\mathrm{b}}$.\n    - OT-II CD$4^{+}$ T cells specific for $OVA_{323–339}$–$I-A^{\\mathrm{b}}$.\n  - **Readout:** Interferon-gamma (IFN-$\\gamma$) production measured by ELISA at $18\\,\\mathrm{h}$.\n  - **Orthogonal Controls:** Measurement of fluorescent $\\mathrm{OVA}$ uptake and cell viability by propidium iodide exclusion.\n\n- **Objective:** Design an experiment to discriminate the effects of inhibiting cytosolic versus endo/lysosomal proteolysis on $\\mathrm{MHC\\,I}$ and $\\mathrm{MHC\\,II}$ presentation, while controlling for effects on peptide loading and cytotoxicity.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against the validation criteria:\n\n- **Scientifically Grounded:** The problem is firmly rooted in the central dogma of cellular immunology, specifically the established pathways for antigen processing and presentation by $\\mathrm{MHC\\,I}$ and $\\mathrm{MHC\\,II}$ molecules. The experimental system described—using $\\mathrm{BMDCs}$, the $\\mathrm{OVA}$ antigen model, specific $\\mathrm{T}$ cell clones ($\\mathrm{OT-I}$, $\\mathrm{OT-II}$), and well-characterized pharmacological inhibitors ($\\mathrm{MG132}$, $\\mathrm{E64d}$, $\\mathrm{pepstatin\\,A}$)—is a canonical and widely published model for studying these processes. All premises are factually correct and represent consensus knowledge in the field.\n- **Well-Posed:** The problem is clearly defined. It asks for the assembly of provided experimental components into a valid design and the prediction of outcomes based on the provided principles. The information is sufficient to deduce a unique set of expected results and to evaluate the appropriateness of the proposed experimental designs.\n- **Objective:** The language is technical, precise, and devoid of subjective or ambiguous terminology. All elements are quantifiable and testable.\n\nThe problem statement exhibits none of the invalidity flaws. It is not scientifically unsound, non-formalizable, incomplete, unrealistic, or ill-posed. It presents a standard, albeit complex, scientific reasoning task.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. The solution will proceed with a full derivation and option analysis.\n\n### Derivation of Expected Outcomes\n\nBased on the provided principles, we can predict the outcome of each experimental condition. The key is to trace the path of each antigen type and determine its dependence on the proteasome versus lysosomal proteases.\n\n1.  **Presentation of Cytosolic Antigen ($\\mathrm{cOVA}$):**\n    - $\\mathrm{cOVA}$ is synthesized in the cytosol. For presentation on $\\mathrm{MHC\\,I}$ to $\\mathrm{OT-I}$ T cells, it must be degraded by the proteasome.\n    - Effect of $\\mathrm{MG132}$ (proteasome inhibitor): Will block proteasomal degradation of $\\mathrm{cOVA}$, thus **inhibiting** $\\mathrm{OT-I}$ T cell activation.\n    - Effect of $\\mathrm{E64d/pepstatin\\,A}$ (lysosomal protease inhibitors): The canonical $\\mathrm{MHC\\,I}$ pathway does not involve lysosomes. These inhibitors will have **no effect** on $\\mathrm{OT-I}$ T cell activation.\n\n2.  **Presentation of Exogenous Soluble Antigen ($\\mathrm{sOVA}$):**\n    - **For $\\mathrm{MHC\\,II}$ presentation (to $\\mathrm{OT-II}$ T cells):** $\\mathrm{sOVA}$ is endocytosed and processed in lysosomes. This requires lysosomal proteases (e.g., cathepsins, which are targets of $\\mathrm{E64d}$).\n    - Effect of $\\mathrm{E64d/pepstatin\\,A}$: Will block proteolytic cleavage of $\\mathrm{sOVA}$ into the $OVA_{323–339}$ peptide, thus **inhibiting** $\\mathrm{OT-II}$ T cell activation.\n    - Effect of $\\mathrm{MG132}$: The canonical $\\mathrm{MHC\\,II}$ pathway is proteasome-independent. This inhibitor will have **no effect** on $\\mathrm{OT-II}$ T cell activation.\n    - **For $\\mathrm{MHC\\,I}$ cross-presentation (to $\\mathrm{OT-I}$ T cells):** $\\mathrm{sOVA}$ is endocytosed, but must access the cytosol to be degraded by the proteasome. The problem explicitly states this pathway is dependent on proteasome activity.\n    - Effect of $\\mathrm{MG132}$: Will block proteasomal degradation of cytosolic $\\mathrm{sOVA}$, thus **inhibiting** $\\mathrm{OT-I}$ T cell activation.\n    - Effect of $\\mathrm{E64d/pepstatin\\,A}$: These inhibitors act within the lysosome. Since the cytosolic cross-presentation pathway requires antigen to exit the endocytic system for proteasomal processing, blocking lysosomal degradation is not expected to inhibit this pathway. Therefore, these inhibitors will have **no effect** on $\\mathrm{OT-I}$ activation.\n\n3.  **Presentation of Preprocessed Peptides ($\\mathrm{SIINFEKL}$ and $OVA_{323–339}$):**\n    - These peptides are supplied exogenously and have the correct sequence and length to bind directly to their respective $\\mathrm{MHC}$ molecules ($\\mathrm{SIINFEKL}$ to $H-2K^{\\mathrm{b}}$; $OVA_{323–339}$ to $I-A^{\\mathrm{b}}$), bypassing all upstream proteolytic processing steps.\n    - Effect of $\\mathrm{MG132}$ or $\\mathrm{E64d/pepstatin\\,A}$: Neither inhibitor should affect the presentation of preprocessed peptides. A lack of inhibition in these control conditions is critical to demonstrate that the inhibitors are specifically targeting proteolysis and not causing general toxicity or interfering with peptide loading, $\\mathrm{MHC}$ surface expression, or T cell co-culture.\n\n4.  **Orthogonal Controls:**\n    - Uptake and viability controls are essential to confirm that any observed inhibition of T cell activation is due to a specific block in antigen processing, not to a trivial effect like preventing antigen entry into the cell or killing the $\\mathrm{BMDCs}$. The inhibitors are expected to have **no effect** on these parameters under appropriately titrated concentrations.\n\n### Evaluation of Options\n\n**A. Treat BMDCs with MG132 or E64d/pepstatin as described; deliver cOVA, sOVA, or preprocessed peptides; then co-culture with OT-I or OT-II and quantify IFN-$\\gamma$. Predicted outcomes: with cOVA, MG132 markedly reduces OT-I responses while E64d/pepstatin has no effect; with sOVA, MG132 reduces OT-I cross-presentation whereas E64d/pepstatin reduces OT-II responses; for peptide-pulsed BMDCs (SIINFEKL or $OVA_{323–339}$), neither MG132 nor E64d/pepstatin reduces IFN-$\\gamma$ from OT-I or OT-II, indicating that proteolysis is bypassed. Fluorescent OVA uptake and viability are unchanged across inhibitor and vehicle groups.**\n\n- **Experimental Design:** The design is comprehensive. It tests both cytosolic and exogenous antigens, uses both $\\mathrm{MHC\\,I}$ and $\\mathrm{MHC\\,II}$ readouts, and crucially includes the preprocessed peptide controls.\n- **Predicted Outcomes:** The predictions perfectly match the logical derivations above.\n  - $\\mathrm{cOVA} \\rightarrow \\mathrm{OT-I}$ is correctly identified as proteasome-dependent.\n  - $\\mathrm{sOVA} \\rightarrow \\mathrm{OT-II}$ is correctly identified as lysosome-dependent.\n  - $\\mathrm{sOVA} \\rightarrow \\mathrm{OT-I}$ (cross-presentation) is correctly identified as proteasome-dependent.\n  - The peptide controls are correctly predicted to be unaffected by the inhibitors, demonstrating specificity.\n  - The orthogonal controls for uptake and viability are correctly included and predicted to be unchanged.\n- **Verdict:** **Correct**. This option describes a robust, well-controlled experiment with accurate predictions.\n\n**B. Treat BMDCs with MG132 or E64d/pepstatin; deliver only sOVA; co-culture with OT-I and OT-II. Predicted outcomes: MG132 reduces both OT-I and OT-II responses, and E64d/pepstatin has no effect on either response. Peptide-pulsed controls are not needed because inhibitors act only upstream of peptide–MHC loading.**\n\n- **Experimental Design:** The design is incomplete. It omits $\\mathrm{cOVA}$, failing to test the canonical $\\mathrm{MHC\\,I}$ pathway directly. It also omits the essential peptide controls.\n- **Predicted Outcomes:** The predictions are incorrect. $\\mathrm{MG132}$ should not reduce the $\\mathrm{OT-II}$ response to $\\mathrm{sOVA}$. $\\mathrm{E64d/pepstatin\\,A}$ absolutely should reduce the $\\mathrm{OT-II}$ response to $\\mathrm{sOVA}$. The justification for omitting controls is a logical fallacy; the controls are necessary to prove the stated assumption.\n- **Verdict:** **Incorrect**.\n\n**C. Treat BMDCs with MG132 or E64d/pepstatin; deliver cOVA, sOVA, and preprocessed peptides; co-culture with OT-I and OT-II. Predicted outcomes: both inhibitors reduce OT-I and OT-II responses for all antigen formats, including preprocessed peptides, because both proteasomes and lysosomal proteases are broadly required for peptide–MHC stability. Uptake and viability controls are unnecessary.**\n\n- **Experimental Design:** The set of conditions is appropriate.\n- **Predicted Outcomes:** The predictions are grossly incorrect. They suggest a non-specific, global inhibition, which contradicts the known specific mechanisms of the inhibitors and pathways. The claim that inhibitors would block responses to preprocessed peptides is fundamentally wrong and contradicts a given principle. The scientific justification regarding $\\mathrm{pMHC}$ stability is also incorrect in this context. The dismissal of viability controls is unacceptable experimental practice.\n- **Verdict:** **Incorrect**.\n\n**D. Treat BMDCs with MG132 or E64d/pepstatin; deliver cOVA and sOVA; co-culture only with OT-I. Predicted outcomes: MG132 reduces OT-I responses to sOVA but not to cOVA; E64d/pepstatin reduces OT-I responses to cOVA but not to sOVA. Peptide-pulsed controls are omitted because they cannot inform processing steps.**\n\n- **Experimental Design:** The design is incomplete. It omits the $\\mathrm{OT-II}$ readout, making it impossible to evaluate the $\\mathrm{MHC\\,II}$ pathway, which is a stated goal of the experiment. It also omits the peptide controls.\n- **Predicted Outcomes:** The predictions are incorrect. $\\mathrm{MG132}$ should inhibit $\\mathrm{OT-I}$ responses to *both* $\\mathrm{sOVA}$ (cross-presentation) and $\\mathrm{cOVA}$ (canonical pathway). The prediction that $\\mathrm{E64d/pepstatin\\,A}$ reduces OT-I responses to $\\mathrm{cOVA}$ is biologically baseless, as the cytosolic pathway does not involve lysosomal proteases. The justification for omitting controls is, again, fallacious.\n- **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}